Ranbaxy Laboratories on Monday said it has received final approval from the United States Food and Drugs Administration to manufacture and market Amoxicillin and Clavulnate Potassium tablets, a generic version of GlaxoSmithkline's Augmentin.

The total market for all forms of Amoxicillin and Clavulnate Potassium is estimated at $31.4 million, a Ranbaxy statement said in New Delhi.

The drug is indicated in the treatment of infections caused by susceptible strains designated organisms in conditions such as lower respiratory tract infections, otitis media, sinussitis, skin and skin structure infections and urinary tract infections.

Commenting on the approval, Jim Meehan, vice president, sales and marketing, Ranbaxy, said: "Amoxicillin and Clavulnate Potassium chewable tablets will be made available nationwide through retail pharmacies, wholesalers and distributors as quickly as inventories can be reached."